News | Implantable Cardiac Monitor (ICM) | August 11, 2015

Biotronik Announces First Enrollments in the BIO|GUARD-MI Study

Study evaluates whether early remote detection of cardiac arrhythmias reduces major cardiovascular events in post-acute myocardial infarction patients

Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring

August 11, 2015 — Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early detection of cardiac arrhythmias offered by BioMonitor, and subsequent treatments, reduce the likelihood of major adverse cardiovascular events (MACE). The study will, for the first time ever, examine patients with relatively preserved left ventricular ejection fraction (LVEF > 35 percent), who have experienced acute myocardial infarction (AMI).

BioMonitor is a leadless cardiac monitor implanted under the skin, intended to track cardiac electric activity and provide long-term remote monitoring of patients with arrhythmias. It uses Biotronik Home Monitoring for the automatic daily transmission of information on both the patient's clinical and device status.

"From previous study results, we already know just how important cardiac arrhythmia can be as an indicator of further critical events in heart patients," commented coordinating clinical investigator Christian Jons, Rigshospitalet Heart Center, Copenhagen, Denmark. "The question now, which we hope to address with the BIO|GUARD-MI study, is whether highly accurate and reliable monitoring tools like BioMonitor with Home Monitoring, can help us identify early warning signs, thereby leading to faster treatment while minimizing direct interference in patients' lives."

A previous study indicated that a cardiac arrhythmia is the most powerful predictor for a MACE in post-AMI patients who have an LVEF ≤ 40 percent. Of these patients, 20 percent experienced a major cardiovascular event within two years. From those, more than 80 percent were diagnosed with a cardiac arrhythmia before the event by using an implantable cardiac monitor. However, the patient group with a relatively preserved ejection fraction after AMI is quite large, but until now underrepresented in clinical studies. 80-90 percent of patients who survive AMI have relatively preserved ejection fraction with LVEF > 35 percent. BIO|GUARD-MI will now look at whether these patients receive similar benefits from using BioMonitor, as patients with lower LVEF.

The prospective, controlled, randomized, multicenter trial will enroll 2,900 patients in approximately 35 centers worldwide. The primary endpoint is the time from randomization to the first MACE.

For more information: www.biotronik.com

Related Content

The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack.

 The Angel Medical Systems' AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. 

Technology | Implantable Cardiac Monitor (ICM) | May 09, 2018
 May 9, 2018 — The U.S.
Abbott SJM St. Jude Confirm RX implantable cardiac monitor (ICM).

The Abbott Confirm RX implantable cardiac monitor (ICM) is smaller than a computer thumb-drive and in implanted in a simple in-office procedure just under the skin.

Technology | Implantable Cardiac Monitor (ICM) | October 23, 2017
October 23, 2017 – The U.S.
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM) | April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM) | March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ
News | Implantable Cardiac Monitor (ICM) | March 14, 2017
Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM) | February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
Biotronik, BioMonitor 2 implantable cardiac monitor, BioInsight clinical study, first patients enrolled
News | Implantable Cardiac Monitor (ICM) | January 20, 2017
Biotronik has enrolled the first patients in the BioInsight clinical study evaluating the safety and feasibility of...
CardioMEMS, implantable hemodynamic monitor, Fontan anatomy, Nationwide Children's Hospital, Wexner Medical Center
News | Implantable Cardiac Monitor (ICM) | May 02, 2016
In a recent case series, clinicians from The Heart Center at Nationwide Children’s Hospital and The Ohio State...
Medtronic, Reveal Linq ICM, in-office insertion, RIO 2 study
News | Implantable Cardiac Monitor (ICM) | July 16, 2015
Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal...
Overlay Init